Angina Pectoris Overview

Angina pectoris is a condition characterized by chest pain or discomfort that arises when the heart muscle does not receive enough oxygen relative to its metabolic demands. Understanding angina requires knowledge of cardiac anatomy, coronary circulation, and the mechanisms by which oxygen supply and demand become unbalanced. This chapter establishes the foundational concepts needed to comprehend how and why anginal symptoms develop.

The term angina pectoris derives from two Latin words: angere, meaning to strangle or choke, and pectoris, meaning chest. This etymological foundation captures the clinical presentation—patients often describe a sensation of chest tightness or strangling. Angina is a common condition and, if not properly managed, can lead to more serious cardiovascular diseases.

The heart comprises three principal tissue layers, each with distinct structure and function. The pericardium is the outermost layer—a fibrous sac that surrounds and protects the entire heart while allowing it to contract freely. Beneath the pericardium lies the myocardium, the thick muscular layer composed of cardiac muscle fibers responsible for the heart's pumping action and generation of contractile force. The innermost layer, the endocardium, lines the heart's chambers and provides a smooth surface in contact with blood; damage to this layer can trigger thrombosis.

While hypoxia and ischemia both impair oxygen availability to tissues, they arise through different mechanisms: hypoxia reflects a problem with oxygen availability in the blood or tissues (such as in carbon monoxide poisoning or high altitude), whereas ischemia reflects a circulatory problem—poor blood perfusion. Infarction represents the most severe outcome: persistent ischemia lasting long enough to cause irreversible cell death and tissue necrosis. Understanding this spectrum is essential because angina represents the reversible, early stage of cardiac oxygen deprivation, whereas myocardial infarction (MI) represents irreversible tissue damage.

Angina pectoris fundamentally results from a mismatch between oxygen demand by the myocardium and oxygen supply through coronary circulation. All organs and tissues require oxygen and nutrients to generate adenosine triphosphate (ATP), the energy currency that powers cellular processes. The heart, being a continuously contracting muscle with high metabolic demands, is particularly vulnerable to oxygen shortages. When oxygen supply falls short of demand, the myocardium rapidly transitions from aerobic (oxygen-dependent) metabolism to less efficient anaerobic pathways, producing lactate and hydrogen ions that accumulate and trigger chest pain.

Adenosine triphosphate (ATP) is synthesized through a metabolic cascade: glucose is broken down to pyruvate through glycolysis, pyruvate enters mitochondria and is converted to acetyl-CoA by pyruvate dehydrogenase, and acetyl-CoA enters the Krebs cycle (citric acid cycle) to generate the reduced coenzymes that power oxidative phosphorylation in the electron transport chain. When oxygen is abundant, this aerobic pathway is highly efficient. Under ischemic conditions, however, the cardiac myocyte loses the terminal electron acceptor (oxygen) and cannot complete oxidative phosphorylation; glycolysis continues but produces only lactate and minimal ATP, rapidly depleting the cell's energy reserves and impairing contractile function.

The coronary arteries are the blood vessels that deliver oxygen and nutrients to the myocardium itself. Unlike most organs that extract oxygen from blood passing through their capillaries, the heart relies entirely on its intrinsic coronary circulation—the heart muscle cannot extract oxygen efficiently from the blood contained within its chambers. This anatomical dependency means that any obstruction, narrowing, or vasospasm of the coronary arteries directly compromises oxygen delivery. Normal coronary flow automatically increases during periods of increased cardiac workload (such as exercise or excitement) to meet the heightened metabolic demands; if coronary vessels cannot dilate sufficiently or are already partially occluded, oxygen supply becomes inadequate and anginal symptoms emerge.

Angina pectoris arises fundamentally from an imbalance between myocardial oxygen demand and oxygen supply. The heart muscle requires a constant blood supply to generate the ATP needed for contraction; when perfusion becomes insufficient relative to metabolic needs, ischemia develops and anginal pain results. Understanding the specific mechanisms that create this mismatch—atherosclerotic narrowing, thrombotic occlusion, and vasospasm—is essential to grasping why different anginal syndromes present with distinct characteristics and treatment responses.

Atherosclerosis is the primary pathological driver of angina in the majority of patients. Dyslipidemia—elevated circulating lipids, particularly low-density lipoprotein cholesterol—promotes the deposition of lipid-rich material within the coronary arterial walls, initiating plaque formation. Over time, these atherosclerotic plaques accumulate cholesterol, smooth muscle cells, and inflammatory debris, progressively thickening the intimal layer and reducing the vessel's luminal diameter.

As atherosclerotic plaques enlarge, they physically narrow the vessel lumen and increase total peripheral vascular resistance (TPR). This hemodynamic change elevates blood pressure and creates turbulent flow patterns, both of which can destabilize the plaque's fibrous cap, predisposing it to rupture or erosion. When luminal narrowing reaches a critical threshold—typically greater than 70% diameter stenosis—the vessel can no longer accommodate increases in coronary blood flow during heightened oxygen demand, leading to demand-induced ischemia and anginal symptoms.

Plaque rupture or erosion exposes thrombogenic material to circulating blood, triggering platelet activation and aggregation. Platelets adhere to the exposed collagen and tissue factor, forming a primary hemostatic plug that rapidly grows as additional platelets are recruited through a cascade of adhesion and activation signals. Simultaneously, the tissue factor pathway initiates the coagulation cascade, leading to thrombin generation and cross-linked fibrin deposition. The resulting thrombus may partially or completely occlude the already-narrowed lumen, acutely reducing coronary blood flow below the critical level needed to sustain myocardial metabolism.

When a thrombus completely blocks a coronary artery, the myocardium downstream of the occlusion becomes severely hypoxic and then enters ischemia. Persistent ischemia lasting more than a few minutes leads to irreversible myocyte necrosis and myocardial infarction (MI). This progression from chronic atherosclerotic narrowing to acute thrombotic occlusion represents the pathological bridge between stable angina (which involves intermittent, reversible ischemia) and unstable angina or MI (which involve acute thrombotic events and greater tissue injury).

Beyond atherosclerotic narrowing and thrombosis, abnormal constriction of coronary arteries—vasospasm—can precipitate anginal symptoms. Intrinsic vasospasm involves excessive smooth muscle contraction in response to physiological or pathological triggers, often in the absence of significant atherosclerotic plaque. Elevated sympathetic tone, circulating catecholamines, and endothelial dysfunction all predispose to vasospastic episodes. Vasospasm narrows the vessel lumen transiently, reducing coronary flow and inducing ischemia; when the spasm resolves, perfusion is restored and symptoms abate, often without any underlying atherosclerotic disease or thrombosis. This mechanism is characteristic of variant (Prinzmetal) angina, which typically occurs at rest and may show distinctive electrocardiographic changes such as ST elevation during symptomatic episodes.

Stable angina is the most common and predictable form of angina pectoris. It arises from an imbalance between myocardial oxygen demand and oxygen supply, typically triggered by increased metabolic activity of the heart. The classic triggers include physical exercise, emotional excitement, and exertion—all of which elevate the heart's demand for oxygen beyond what the narrowed coronary arteries can deliver through atherosclerotic plaques.

Relief of stable angina is prompt and predictable: rest immediately reduces oxygen demand, and organic nitrates such as isosorbide mononitrate, isosorbide dinitrate, and glyceryl trinitrate provide rapid vasodilation and symptom resolution. This responsiveness to nitrates and rest is a defining diagnostic feature that distinguishes stable angina from other forms.

Unstable angina differs fundamentally from stable angina in both mechanism and danger. It is caused by thrombosis—the formation of a blood clot on a disrupted atherosclerotic plaque—which partially or transiently occludes a coronary artery. Unlike stable angina, unstable angina can occur at rest without any obvious trigger, is more severe and painful, and is unpredictable in its onset.

A critical clinical distinction is that unstable angina does not respond reliably to rest or organic nitrates, making it more dangerous and requiring urgent intervention. Thrombolytic therapy (medications that dissolve blood clots) is the appropriate treatment, whereas nitrates are ineffective because the problem is not simply reduced oxygen supply from atherosclerosis but active thrombotic occlusion. Unstable angina represents a medical emergency and carries a higher risk of progressing to myocardial infarction.

Variant angina, also called Prinzmetal angina, has a different pathophysiologic basis: it is caused by vasospasm—spontaneous constriction of a coronary artery—rather than by plaque burden or thrombosis. This type can occur at any time, including at rest or during sleep, and does not follow the exercise-induced pattern of stable angina. The vasospastic episodes cause transient but severe reductions in coronary blood flow.

The electrocardiographic hallmark of variant angina is transient ST-segment elevation during the anginal episode, a finding that reflects the acute transmural ischemia caused by the vasospastic event. This ST elevation distinguishes variant angina from stable angina (which typically shows ST depression or T-wave changes) and makes it recognizable on a 12-lead electrocardiogram during an acute attack.

Understanding these three types is critical for clinical management. Stable angina, while limiting, is generally manageable with lifestyle modification and medications; unstable angina demands urgent attention and thrombolytic or antiplatelet intervention to prevent progression to myocardial infarction; and variant angina requires recognition of its vasospastic nature to avoid inappropriate therapy and to deploy vasodilators effectively.

Angina pectoris presents with characteristic chest heaviness and dyspnea (shortness of breath) that reflect the heart's oxygen deprivation. The term itself derives from Latin: angere (to strangle or choke) and pectoris (chest), capturing the patient's subjective experience of constriction. This pain or discomfort is the hallmark symptom, often described as pressure, tightness, or squeezing rather than sharp pain.

Pain radiation is a critical diagnostic feature: anginal discomfort typically radiates to the back, shoulders, neck, and jaw. This referral pattern reflects the shared sympathetic innervation of the heart and these remote sites. Recognition of radiation is essential because it distinguishes true angina from musculoskeletal or gastrointestinal causes that present with localized chest pain alone.

Symptoms vary by anginal type. Stable angina is triggered by increased oxygen demand—exercise, excitement, or exertion elevate heart workload and precipitate chest discomfort in patients with fixed atherosclerotic stenosis. Symptoms are predictable and reproducible; the same activity reliably provokes angina. Relief occurs with rest, which lowers metabolic demand, or with pharmacological intervention.

Unstable angina and variant (Prinzmetal) angina present differently. Unstable angina occurs unpredictably, often at rest, and is caused by acute thrombus formation or plaque rupture; it is more severe and dangerous than stable angina and does not respond reliably to nitrates or rest. Variant angina results from coronary vasospasm rather than fixed obstruction and can occur at any time, particularly in early morning hours. These distinctions guide urgency of intervention and choice of therapy.

Anti-platelet agents form the backbone of angina prevention and acute thrombotic event management. Aspirin irreversibly inhibits cyclooxygenase, preventing platelet aggregation and thrombus formation. Clopidogrel (and related P2Y12 inhibitors) block adenosine diphosphate signaling on platelets, providing complementary anti-platelet activity. In unstable angina, where thrombus formation is the primary mechanism, dual anti-platelet therapy (aspirin plus clopidogrel) reduces recurrent ischemic events.

Organic nitrates (isosorbide mononitrate, isosorbide dinitrate, and glyceryl trinitrate) are rapid-acting vasodilators that relieve acute anginal episodes and reduce frequency in stable angina. These agents work by donating nitric oxide, which relaxes vascular smooth muscle and dilates both epicardial coronary arteries and resistance vessels. They lower preload and afterload, reducing myocardial oxygen demand. Nitrates are particularly effective in stable angina but have limited efficacy in unstable angina where occlusive thrombus, not just spasm or demand mismatch, is the underlying problem.

Tolerance to chronic nitrate therapy develops due to reduced bioavailability of nitric oxide precursors; intermittent dosing or a nitrate-free interval (typically 10–14 hours daily) maintains efficacy. In variant angina caused by vasospasm, nitrates provide symptomatic relief, and calcium channel blockers (which also relax vascular smooth muscle) are often added for longer-term control.

Dyslipidemia is a major risk factor for atherosclerotic plaque formation and is present in most stable angina patients. Lipid-lowering drugs, particularly statins (HMG-CoA reductase inhibitors) and lipase inhibitors, reduce circulating low-density lipoprotein cholesterol and stabilize existing plaques. By lowering lipid burden, these agents reduce plaque progression, diminish the frequency of anginal episodes, and lower the risk of acute coronary syndromes. Treatment is particularly important in stable angina, where atherosclerotic stenosis is the fixed anatomical problem.

Chest pain has a broad differential diagnosis; not all chest discomfort signals angina. Gastroesophageal reflux disease (GERD) produces substernal burning pain often worse supine or after meals, but is not associated with exertion and lacks radiation to the back and shoulders. Pneumonitis causes pleuritic (sharp, positional) chest pain that worsens with deep breathing and is accompanied by respiratory symptoms. Costochondritis presents with reproducible tenderness over costal cartilages and is localized to the chest wall without radiation.

Key differentiating features are exertional onset, relief by rest or nitrates, and radiation to remote sites—all hallmarks of angina but absent in mimics. Electrocardiography (ECG), especially during symptoms, is crucial: stable angina may show reversible ST-segment depression during ischemia (indicating subendocardial hypoperfusion), while variant angina classically shows ST-segment elevation. Troponin levels remain normal in angina but rise in acute myocardial infarction. Clinical judgment, symptom character, and imaging findings guide the differential.

Treatment efficacy is assessed by reduction in symptom frequency, increased exercise tolerance, and freedom from rest pain. In stable angina, symptom relief is the primary goal; successful therapy allows patients to resume normal activities without limiting chest discomfort. Response to therapy also informs diagnosis: rapid relief with sublingual nitrates (within 5 minutes) strongly suggests true angina, whereas lack of response may indicate an alternative diagnosis or, in unstable angina, inadequate acute treatment.

In unstable angina, treatment success means prevention of myocardial infarction, recurrent ischemic events, and stabilization of the acute thrombotic state. Anti-platelet therapy, anticoagulation, and aggressive lipid management form the cornerstone; nitrates provide symptomatic relief but are insufficient as monotherapy. Follow-up imaging (stress testing, coronary angiography) stratifies risk and guides revascularization decisions. Variant angina responds well to calcium channel blockers and nitrates; recurrence of spasm-related symptoms signals need for therapy adjustment.